HAYA Co-Founder & CEO Samir Ounzain discusses the WISPER target that came out of the company's work of cataloging long non-coding RNAs, and the role that downregulating it might play in stopping the progression of nonobstructive hypertrophic cardiomyopathy. Plus, other programs, and where an understanding of the regulatory portion of the genome could ultimately take us. Coverage brought to you by

Samir Ounzain explains the way HAYA studies how long non-coding RNAs, a once poorly understood component of the genome, affects disease...